Helix BioPharma (TSE:HBP) Shares Cross Below Two Hundred Day Moving Average – What’s Next?

Helix BioPharma Corp. (TSE:HBP)’s share price crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of C$2.05 and traded as low as C$1.58. Helix BioPharma shares last traded at C$1.58, with a volume of 128 shares.

Helix BioPharma Price Performance

The company has a debt-to-equity ratio of 2.34, a current ratio of 0.04 and a quick ratio of 1.04. The business has a fifty day moving average of C$1.84 and a 200 day moving average of C$2.05. The stock has a market cap of C$120.68 million, a PE ratio of -26.33 and a beta of 0.40.

Helix BioPharma (TSE:HBP) last announced its quarterly earnings results on Monday, March 16th. The biopharmaceutical company reported C($0.01) earnings per share for the quarter. Sell-side analysts anticipate that Helix BioPharma Corp. will post -0.11 earnings per share for the current year.

About Helix BioPharma

Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today’s hardest-to-treat cancers. The Company’s pipeline is led by Tumor Defense Breaker¿ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today’s front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix’s next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery.